Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan

PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Kun-Ming, Ou-Yang, Fu, Chao, Ta-Chung, Kuo, Yao-Lung, Cheng, Tsui-Fen, Chao, Tsu-Yi, Chen, Dar-Ren, Tzeng, Yen-Dun, Wang, Being-Whey, Liu, Chun-Yu, Hu, Ming-Hung, Lu, Yin-Che, Ou, Wei-Jen, Kuo, Chin-Ho, Chuang, Chieh-Han, Kan, Jung-Yu, Chen, Fang-Ming, Hou, Ming-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022524/
https://www.ncbi.nlm.nih.gov/pubmed/29623575
http://dx.doi.org/10.1007/s10549-018-4778-y
_version_ 1783335696596992000
author Rau, Kun-Ming
Ou-Yang, Fu
Chao, Ta-Chung
Kuo, Yao-Lung
Cheng, Tsui-Fen
Chao, Tsu-Yi
Chen, Dar-Ren
Tzeng, Yen-Dun
Wang, Being-Whey
Liu, Chun-Yu
Hu, Ming-Hung
Lu, Yin-Che
Ou, Wei-Jen
Kuo, Chin-Ho
Chuang, Chieh-Han
Kan, Jung-Yu
Chen, Fang-Ming
Hou, Ming-Feng
author_facet Rau, Kun-Ming
Ou-Yang, Fu
Chao, Ta-Chung
Kuo, Yao-Lung
Cheng, Tsui-Fen
Chao, Tsu-Yi
Chen, Dar-Ren
Tzeng, Yen-Dun
Wang, Being-Whey
Liu, Chun-Yu
Hu, Ming-Hung
Lu, Yin-Che
Ou, Wei-Jen
Kuo, Chin-Ho
Chuang, Chieh-Han
Kan, Jung-Yu
Chen, Fang-Ming
Hou, Ming-Feng
author_sort Rau, Kun-Ming
collection PubMed
description PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. CONCLUSIONS: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women.
format Online
Article
Text
id pubmed-6022524
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-60225242018-07-06 Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan Rau, Kun-Ming Ou-Yang, Fu Chao, Ta-Chung Kuo, Yao-Lung Cheng, Tsui-Fen Chao, Tsu-Yi Chen, Dar-Ren Tzeng, Yen-Dun Wang, Being-Whey Liu, Chun-Yu Hu, Ming-Hung Lu, Yin-Che Ou, Wei-Jen Kuo, Chin-Ho Chuang, Chieh-Han Kan, Jung-Yu Chen, Fang-Ming Hou, Ming-Feng Breast Cancer Res Treat Epidemiology PURPOSE: The aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer. METHODS: This retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer. RESULTS: The survival rate at 24 months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or more. Eight patients (1.83%) had complete remission, 82 (18.8%) had partial remission, 202 (46.3%) had stable disease, and 144 (33.0%) had progressive disease (PD). Patients’ tumors with the luminal A subtype had a significantly better objective response rate. Kaplan–Meier analysis indicated that hormone receptor positivity, luminal A subtype, receipt of eribulin as the 1st to 3rd line therapy, and metastasis to fewer than 4 organs were significantly associated with longer TTF. Stepwise multivariate analysis showed that only receipt of eribulin as the 1st to 3rd line therapy was significantly associated with TTF (HR 1.49, p < 0.001). All toxicities were manageable and only 18 patients (4.1%) discontinued treatment due to adverse events. CONCLUSIONS: Eribulin appears to have better efficacy and cause fewer adverse events, especially neutropenia, in Taiwanese women than Western women. Springer US 2018-04-05 2018 /pmc/articles/PMC6022524/ /pubmed/29623575 http://dx.doi.org/10.1007/s10549-018-4778-y Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Epidemiology
Rau, Kun-Ming
Ou-Yang, Fu
Chao, Ta-Chung
Kuo, Yao-Lung
Cheng, Tsui-Fen
Chao, Tsu-Yi
Chen, Dar-Ren
Tzeng, Yen-Dun
Wang, Being-Whey
Liu, Chun-Yu
Hu, Ming-Hung
Lu, Yin-Che
Ou, Wei-Jen
Kuo, Chin-Ho
Chuang, Chieh-Han
Kan, Jung-Yu
Chen, Fang-Ming
Hou, Ming-Feng
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title_full Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title_fullStr Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title_full_unstemmed Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title_short Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
title_sort effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in taiwan
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022524/
https://www.ncbi.nlm.nih.gov/pubmed/29623575
http://dx.doi.org/10.1007/s10549-018-4778-y
work_keys_str_mv AT raukunming effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT ouyangfu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chaotachung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT kuoyaolung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chengtsuifen effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chaotsuyi effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chendarren effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT tzengyendun effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT wangbeingwhey effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT liuchunyu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT huminghung effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT luyinche effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT ouweijen effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT kuochinho effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chuangchiehhan effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT kanjungyu effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT chenfangming effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan
AT houmingfeng effectoferibulinonpatientswithmetastaticbreastcancermulticenterretrospectiveobservationalstudyintaiwan